Christian Philipp Pallasch

Status: Independent Research Group Leader

Clinic I of Internal Medicine
University Hospital of Cologne
CECAD Research CenterJoseph-Stelzmannstr. 26
50937 Cologne

Phone: +49 221/478 84128
Nationality: German



1996 - 1998 

University of Saarland, Medical School Homburg/Saar

199 8- 1999

Medical School of the University of Oslo, Norway

1999 - 2003

University of Saarland, Medical School Homburg/Saar

2003 - 2004

University of Cologne, final year internship rotation


Medical and Scientific Training

2000 - 2003

Graduate student at the Institute of Human Genetics Homburg/Saar, Laboratory of E. Meese PhD


Medical thesis, “Prognostic impact of glioblastoma-associated autoantibodies andcharacerization of the immunogenic antigen GLEA2”; summa cum laude

2004 - 2009

Postdoctoral fellow at the University Hospital of Cologne, Laboratory for Cellular Immunotherapy, (Head C.M. Wendter MD)

2004 - 2009

Residency at the Clinic I for Internal Medicine, Department of Hematology and Oncology, University Hospital of Cologne

2009 - 2011

Postdoctoral Fellowship atthe D. Koch Institute for Integrative Cancer Research at MIT, Laboratory of M. HemannPhD


Research Group Leader, University Hospital of Cologne


 Board Exam (general internal medicine, hematology and medical oncology)


Awardsand Prizes


Scholarship for Undergraduate Studies, Ev.StudienwerkVilligst, 1997-2003


Scholarship for graduate students by the German Research Council (DFG) 2000-02


“Eduard-Martin-Preis”, Award for outstanding junior researchers by the Univ. of Saarland


Poster Award at the Annual Meeting of the DGHO Vienna 2008


 Career grant of the Federal Ministry of Innovation, Science, research and Technology, North-Rhine Westfalia.


List of the five most important publications

  1. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT. Sensitizing protective tumor  microenvironments to antibody-mediated therapy. Cell. 2014 Jan 30;156(3):590-602.

  2. Leskov I*, Pallasch CP*, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer  CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 2013 Feb 21;32(8):1066-72.

  3. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 2009 Oct 8;114(15):3255-64.

  4. Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H, Ultsch A, Wickenhauser C, Hallek M, Wendtner CM. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008 Nov 15;112(10):4213-9.

  5. Pallasch CP, Schwamb J, Königs S, Schulz A, Debey S, Kofler D, Schultze JL, Hallek M, Ultsch A, Wendtner CM. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008 Mar;22(3):585-92.